NCT06561087View on ClinicalTrials.gov

Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions

PHASE2RecruitingINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

February 27, 2025

Primary Completion Date

May 30, 2027

Study Completion Date

May 30, 2029

Conditions

Premalignant Lesion

Interventions

DRUG

Nivolumab

Given by injections

Trial Locations (1)

77090

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER